北京中关村科技发展（控股）股份有限公司 关于控股股东一致行动人部分股份延长司法冻结及 司法再冻结期限、被轮候冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）通过 中国证券登记结算有限责任公司查询，获悉： 国美电器有限公司（以下简称：国美电器）作为公司控股股东国美控股集团 有限公司的一致行动人，现持有公司 50,000,000 股流通股，持股比例为 6.64%； 国美电器所持有公司的部分股份被法院延长司法冻结及司法再冻结期限、新增被 法院轮候冻结，具体情况如下： 注：被司法标记股份的案件债权额及执行费用为 7,000 万元；执行人实际需要冻结的本证券的数量为 1,200 万股。 第 1 页 关于控股股东一致行动人部分股份延长司法冻结及司法再冻结期限、被轮候冻结的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-090 股东名称 是否为控股 股东或第一 大股东及其 一致行动人 司法冻结 数量（股） 占其所持 股份比例 占公司总 股本比例 司法冻结 起始日 原司法 ...

本报讯 （记者朱宝琛）为深入贯彻中国证监会及北京市相关工作部署，做好科技金融大文章，提升金 融支持科技创新质效，服务北京国际科技创新中心建设，8月15日，北京证监局、中国人民银行北京市 分行、北京市科学技术委员会、中关村科技园区管理委员会与北京基金小镇共同举办"中关村科技·金融 汇"第6期投贷联动融资对接活动。 北京证监局私募处处长在主持发言中介绍了北京辖区股权创业投资机构、科技型企业和银行投融资方面 的现实需求和结合点，推动投贷联动融资对接的原则和意义，表示将与各委办局合力搭建具有北京特色 创新性的供需对接平台，围绕首都高精尖产业结构、科创型企业成长周期提供更优质、高效的服务；人 民银行北京市分行负责人介绍了投贷联动平台建设和支持私募基金、科创企业发展方面的情况，以及前 期投贷联动融资对接取得的积极成效；北京基金小镇相关负责人介绍了小镇私募机构发展情况，服务实 体经济情况，以及小镇在服务和引导管理人合规展业方面开展的风险防控、合规培训等方面的做法和成 效。 本次活动聚焦"投贷联动"，为科技型企业搭建股权融资与债权融资高效对接的"桥梁"，臻知医学、星川 新能源、平方和、东方空间、华龛生物、泰科天润、大橡科技等 ...

Core Viewpoint - The launch of three service platforms in the IC PARK aims to address the testing shortcomings in the integrated circuit field in Beijing and the surrounding Jing-Jin-Ji region, enhancing the efficiency of chip design and development processes [1] Group 1: Service Platforms - The three newly launched service platforms include a high-speed signal testing laboratory, a high-end advanced packaging technology service center, and a power cycling and transient thermal testing laboratory, all focusing on common technologies in the chip sector [1] - The high-speed signal testing laboratory specifically targets applications in satellite communication, automotive navigation, and data center high-speed interconnects, making it one of the few laboratories in the market with systematic testing capabilities [1] Group 2: Industry Impact - The increasing data volume and the corresponding demand for faster chip data processing speeds highlight the importance of testing chip information transmission speeds during the research and development process [1] - Previously, many small and medium-sized enterprises in Beijing had to send chips to southern regions for testing, which incurred costs and delayed the R&D process by several days; the new laboratory significantly improves R&D efficiency by allowing local testing [1] - The primary investment in chip design R&D is in human resources, and by saving time in the development process, the new facilities help companies reduce costs [1]

Core Points - Zhongguancun Development Group's subsidiary, Zhongguancun International, has signed a memorandum of cooperation with Johor Land Group from Malaysia [1] - The collaboration will focus on sharing technological innovation resources and establishing the Johor Innovation Center (JIC) [1] - The partnership aims to create a technology industry service ecosystem targeting the Johor-Singapore Economic Special Zone [1]

Core Points - The completion and acceptance of the Zhongguancun Third Primary School Yongxin Branch will provide 720 quality educational slots in the northern Haidian area, promoting balanced educational development in Haidian [1] - The school serves as an important supporting facility for the Yongfeng High-tech Industrial Base, facilitating a positive cycle of attracting talent through quality education [1] - This project is a key initiative to implement the "14th Five-Year" education layout, with plans for a group-based school model that includes resource sharing and teacher exchanges to maintain educational quality [1] - The school is currently finalizing teaching equipment and has completed pre-service training for the first batch of teachers, with classes set to officially start on September 1 [1]

2025年8月13日下午，中关村发展集团召开干部大会，宣布北京市委、市政府关于中关村发展集团主要 领导任职的决定：李妍同志任中关村发展集团股份有限公司党委书记、董事长，杨仁全同志任中关村发 展集团股份有限公司党委副书记、董事、总经理。有关市领导，市委组织部、市国资委相关领导及处室 负责人，中关村发展集团领导班子成员、总部各部门正副职和子公司主要负责人参加会议。 来源：中关村发展集团 转自：北京日报客户端 中关村发展集团召开干部大会宣布主要领导任职决定 ...

Group 1 - The company held an investor relations event on August 13, attracting major institutions like Tianfeng Securities and Caitong Fund, where executives detailed the company's product layout and answered questions [1] - The focus of the event included the company's layout in narcotic drugs, market prospects for existing products, and exploration results in cutting-edge fields like mRNA [1] Group 2 - The company has accelerated its narcotic drug layout, with the sublingual tablet of dihydroetorphine hydrochloride being a key product, showing high growth potential [2] - The company has accumulated extensive experience in abuse-resistant sustained-release formulations, which are applied in multiple product developments [2] - The strict regulation of narcotic drugs creates a unique competitive barrier for companies like the company, which is one of the few manufacturers in this field [3] Group 3 - The company has identified significant market opportunities for its dihydroetorphine hydrochloride injection, projecting a 742.22% year-on-year revenue growth for 2024 [3] - The company is the only domestic pharmaceutical enterprise with integrated advantages in raw materials and formulations for dihydroetorphine hydrochloride [3] - The company has established partnerships with other formulation companies to enhance its market position in the raw material market [3] Group 4 - The company is also enhancing its narcotic drug portfolio, with the recent approval of a generic version of tramadol injection, strengthening its market competitiveness [4] Group 5 - The company's mature products, such as bisoprolol fumarate and benidipine hydrochloride, remain important revenue pillars, with the latter capturing a 55% market share in 2022 [5] - The new collection rules for centralized procurement allow for more competitive pricing strategies, which may benefit the company's main products [5] - The company is actively expanding its research and development, including studies on new indications for existing products [6] Group 6 - The company is exploring the mRNA vaccine field, with its self-built platform showing promising results in antigen design and thermal stability [6] - The company aims to establish itself as an "innovative pharmaceutical group" through continuous improvement in its narcotic drug matrix and mRNA vaccine exploration [6]

中关村发布公告称，2025年8月13日，中关村接受天风证券等投资者调研，公司副总裁范秀君、副总裁 兼董事会秘书黄志宇、证券事务代表胡秀梅参与接待，并回答了投资者提出的问题。 （文章来源：每日经济新闻） ...

Group 1: Pain Management and Drug Mechanism - The mechanism of action for dihydroetorphine hydrochloride is more targeted compared to traditional opioids like fentanyl, as it has a significantly higher affinity for mu-opioid receptors [2] - The technology for sustained-release or modified-release formulations is universal and not specific to a single drug, with experience in conventional and abuse-deterrent formulations [2] Group 2: Addiction and Abuse Risk - The addiction and abuse potential of analgesics is closely related to their pharmacological effects, rather than their pharmacokinetics or metabolic pathways, indicating the importance of drug release control and individualized dosing [3] Group 3: Antivertigo Drug Development - The central mechanism of action for phenylpropanolamine hydrochloride involves blocking acetylcholine at M and N receptors, resulting in central and peripheral anticholinergic effects [4] - Research is ongoing to expand indications beyond motion sickness, targeting conditions like Meniere's disease and vestibular neuritis [5] Group 4: Weight Management Drug Comparison - Naltrexone is the only approved drug for weight management in China, acting by antagonizing opioid receptors to suppress eating impulses, differing from the overseas combination product Contrave [6][7] Group 5: mRNA Vaccine Development - The mRNA vaccine utilizes an LNP delivery system, achieving high immunogenicity through a combination of delivery system optimization, antigen design, and immune strategy [8] - The company claims advantages in antigen design, immune durability, and thermal stability compared to competitors, although there is currently no IND or clinical submission timeline [8]

Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]